Abstracts tagged "Anti-TNF Drugs"

Abstract Number: 1191 • ACR Convergence 2020
Specificity for Inflammatory Pathways Associated with Coronary Microvascular Dysfunction in Rheumatoid Arthritis
Brittany Weber¹, Zeling He¹, Sicong Huang¹, Daniel H. Solomon², Elena Massarotti¹, Charlotte Golnik¹, Thany Seyok¹, Seth Brownmiller¹, Laurel Martell¹, Leann Barrett¹, Courtney Bibbo¹, Marcy Bolster³, Marcelo DiCarli¹ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham & Women's Hospital and Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Concord, MA
Background/Purpose: Coronary microvascular disease (CMD) is associated with increased mortality in RA independent of traditional cardiovascular (CV) risk factors. Inflammation likely plays an important role…
Abstract Number: 1638 • ACR Convergence 2020
Systemic Treatment in Behçet’s Disease According to Clinical Phenotypes. Study of 111 Patients
David Martinez-Lopez¹, Lara Sanchez-Bilbao², Carmen Alvarez-Reguera², Alba Herrero Morant², Inigo Gonzalez-Mazon³, José Luis Martín-Varillas⁴, Guillermo Suarez-Amorin², Patricia Setien-Preciados², Cristina Mata-Arnaiz⁵, Miguel Ángel González-Gay⁶ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Bezana, Spain, ⁴Hospital Sierrallana, Torrelavega, Spain, ⁵Hospital de Laredo, Santander, Spain, ⁶Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Behçet’s disease (BD) is a multisystemic vasculitis. Different clinical phenotypes can be distinguished. Systemic corticosteroids are the most used drugs in BD. Conventional and…
Abstract Number: 0199 • ACR Convergence 2020
A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects
Edward C Keystone¹, Daniel Furst*², Jonathan Kay³, EunJin Choi⁴, Antonia Davidson⁵, YunJu Bae⁴, Darin Brimhall⁶, SangJoon Lee⁴, SungHyun Kim⁴ and DaHye Kwak⁴, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celltrion, Inc., Incheon, Republic of Korea, ⁵PPD Development, Austin, TX, ⁶PPD Development, Las Vegas, NV
Background/Purpose: CT-P17 is a recombinant human monoclonal antibody that was developed as the first biosimilar adalimumab with high concentration (100 mg/mL) and citrate-free formulation. The…
Abstract Number: 0718 • ACR Convergence 2020
Obesity Impairs Achievement of Clinical Inactive Disease (CID) in Patients with Juvenile Idiopathic Arthritis (JIA) Treated with TNF Inhibitors
Fabio Basta¹, Denise Pires Marafon², Angela Aquilani³, Maria Isabella Petrone⁴, Andrea Uva⁵, Hanan Jadoun⁶, Aurora Puccacco², Rebecca Nicolai⁶, Silvia Magni Manzoni² and Fabrizio De Benedetti⁷, ¹1 Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy 2 University Center of Autoimmunity, Johannes Gutenberg-University, Mainz, Germany 3 Acura Rheumatology Center Rhineland Palatinate, Bad Kreuznach, Germany, Mainz, Rheinland-Pfalz, Germany, ²Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy, ³Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Lazio, Italy, ⁴Dipartimento Pediatrico Universitario Ospedaliero, Tor Vergata University, Roma, Italy, ⁵Dipartimento Materno-Infantile e Scienze Urologiche, La Sapienza University, Rome, Italy, ⁶Division of Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Lazio, Italy, ⁷Division of Rheumatology, Laboratory of Immuno-Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, Rome, Italy
Background/Purpose: to assess prevalence and disease features associated with obesity in juvenile idiopathic arthritis (JIA) and to evaluate the impact of obesity on the achievement…
Abstract Number: 1226 • ACR Convergence 2020
Outcomes and Efficacy of Selective versus Automatic Switching from Etanercept to a Biosimilar in Inflammatory Arthritis Using Electronic Health Records from UK
Roxanne Cooksey¹, Sinead Brophy¹, Muhammad Azizur¹, Jonathan Kennedy¹ and Ernest Choy², ¹Swansea University, Swansea, Wales, United Kingdom, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom
Background/Purpose: Biosimilars have been approved for the treatment of inflammatory arthritis and evidence from randomised controlled trials have demonstrated equivalent efficacy to biologics. Etanercept biosimilar,…
Abstract Number: 1762 • ACR Convergence 2020
Benefit and Risk Profiles of Janus Kinase Inhibitors Approved in the US for the Treatment of RA
Alvin Wells¹, Kirstin Griffing², Amanda Quebe², Luna Sun², Hong Zhang³ and Paulo Reis², ¹Aurora Rheumatology and Immunotherapy Center, Franklin, ²Eli Lilly and Company, Indianapolis, IN, ³Tech Data Services, King of Prussia, PA
Background/Purpose: In clinical practice, drug treatment decisions must account for the expected benefit from a drug along with its potential risks. Evaluating the number needed…
Abstract Number: 0204 • ACR Convergence 2020
Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects
KyungSang Yu¹, InJin Jang¹, HyeongSeok Lim², JangHee Hong³, MinGul Kim⁴, MinKyu Park⁵, Anhye Kim⁶, MinSoo Park⁷, JaeYong Chung⁸, JongLyul Ghim⁹, SeungHwan Lee¹, SeokKyu Yoon², InSun Kwon³, Daniel Furst*¹⁰, Edward C Keystone¹¹, SangJoon Lee¹², SungHyun Kim¹², YunJu Bae¹², JungBin Cha¹³, HyeJin Kang¹³ and Jonathan Kay¹⁴, ¹Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea, ²College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea, ³Chungnam National University Hospital, Daejeon, Republic of Korea, ⁴College of Medicine, Jeonbuk National University, Jeonbuk, Republic of Korea, ⁵Chungbuk National University Hospital, Cheongju, Republic of Korea, ⁶CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea, ⁷Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁸Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁹Inje University Busan Paik Hospital, Busan, Republic of Korea, ¹⁰Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Celltrion, Inc., Incheon, Republic of Korea, ¹³Celltion, Inc., Incheon, Republic of Korea, ¹⁴University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 was developed as the first biosimilar of the high concentration (100 mg/mL), citrate-free formulation of reference adalimumab. The purpose of this study was…
Abstract Number: 0719 • ACR Convergence 2020
Anti-adalimumab Antibodies Detection Using a Novel Peptide-based Assay in a Cohort of Pediatric Patients with Chronic Rheumatic Disorders: A Pilot Study
Edoardo Marrani¹, Hendrik Rusche², Francesco Terzani³, Elisa Peroni⁴, Feliciana Real-Fernandez⁵, Olivier Monasson⁴, Roberta Ponti⁶, Gabriele Simonini⁷, Anna Maria Papini³ and Paolo Rovero⁵, ¹University of Florence, Firenze, Italy, ²Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, Cergy-Pontoise,, France, ³PeptLab, Dep. Chemistry, University of Florence, Sesto FIorentino, Italy, ⁴Peptlab@CY and Laboratory of Chemical Biology, Cergy-Paris University, cergy-pontoise, France, ⁵PeptLab, Dep. NEUROFARBA, University of Florence, Firenze, Italy, ⁶Pediatric Department, University of Udine, udine, Italy, ⁷Rheumatology Unit, Meyer Children's University Hospital, Florence; NEUROFARBA Department, University of Florence, Italy, Florence, Italy
Background/Purpose: Immunogenicity and development of anti-drug antibodies have been associated with treatment failure and adverse events during biologic treatment. Anti-drug antibodies (ADAs) have been reported…
Abstract Number: 1229 • ACR Convergence 2020
Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
Eulalia Rodriguez-Martín¹, Israel Nieto-Gañán¹, Borja Hernández-Breijo², Cristina Sobrino³, Carlota García-Hoz¹, Javier Bachiller-Corral⁴, Ana Martínez-Feito⁵, Victoria Navarro-Compán⁶, Paloma Lapuente-Suanzes¹, Gema Bonilla⁷, Dora Pascual-Salcedo⁸, Garbiñe Roy¹, Teresa Jurado², Pilar Nozal², Mónica Vázquez⁴, Alejandro Balsa⁷, Luisa M Villar¹ and Chamaida Plasencia⁷, ¹Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ²Hospital Universitario La Paz-Idipaz, Madrid, Spain, ³Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁶Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁷Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFis) are widely used for the treatment of rheumatoid arthritis (RA), although the response rates to this therapy in patients with RA…
Abstract Number: 1872 • ACR Convergence 2020
Relative Associations of Sociodemographic, Clinical and HLA-B Alleles with Enthesitis and Peripheral Arthritis in Patients with Ankylosing Spondylitis
Benjamin Naovarat¹, Lianne Gensler², Michael Ward³, Mark Hwang⁴, Matthew Brown⁵, Amirali Tahanan⁶, Mohammad Rahbar⁶, Mariko Ishimori⁷, Michael Weisman⁸ and John Reveille⁹, ¹The University of Texas McGovern Medical School, Houston, TX, ²University of California San Francisco, San Francisco, CA, ³National Institutes of Health, Bethesda, MD, ⁴McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ⁵Guy's and St Thomas, NHS Foundation Trust and King's College London NIHR Biomedical Research Centre, King's College London, London, United Kingdom, London, United Kingdom, ⁶McGovern Medical School at UTHealth, Houston, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁹Department of Internal Medicine, University of Texas, Houston, TX
Background/Purpose: Previous studies from Latin America have shown an association with peripheral arthritis in patients with spondyloarthritis with HLA-B*15 (as opposed to HLA-B27). We aimed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].